

HYPERA S.A.

A Publicly-Held Corporation

Corporate Taxpayer ID (CNPJ) No. 02.932.074/0001-91

Company Registry (NIRE) 35.300.353.251

CVM Code No. 21431

MATERIAL FACT

HYPERA S.A. (“Company” or “Hypera Pharma”), in compliance with the provisions of article 157, Paragraph 4, of Law No. 6,404 of December 15, 1976, as amended, and the Instruction No. 358 of the Brazilian Securities and Exchange Commission (“CVM”) informs its shareholders and the market in general that it has signed an agreement with Sanofi to acquire 12 brands of over-the-counter and prescription drugs in Brazil, Mexico and Colombia for USD190.3 million (one hundred and ninety million and three hundred thousand dollars) (“Transaction”).

The products to be acquired include, in the Brazilian Consumer Health category, the analgesic **AAS**, the herbal medicine **Naturetti** and the antiseptic **Cepacol**, together with the prescription products **Buclina**, to stimulate appetite, and **Hidantal**, to treat epilepsy, among others. Brazil represented approximately 67% of the net revenue of this portfolio in 2020.

The Transaction is in line with the Company's strategy of strengthening its presence in the Brazilian market through important products that have high growth potential. With the completion of this acquisition, Hypera Pharma will further strengthen its market share in the Consumer Health and Prescription Products segments, especially in the central nervous system and gastrointestinal.

The products to be acquired will also benefit from the Company's robust business platform, which currently has the most modern innovation center and the largest manufacturing complex in Latin America, in addition to a distribution network that reaches 96% of the points of sale in Brazil, which will help to leverage the growth in such markets.

Hypera Pharma and Sanofi will sign a manufacturing and supply agreement in connection with the Transaction, whereby Sanofi will continue to supply products to the Company for a period of up to 3 years. The Transaction is also subject to certain conditions precedent, including the approval by the competent antitrust authorities.

The Company will give more information about the Transaction in the 2Q21 Earnings Conference Call to be held on July 26, 2021.

São Paulo, July 13, 2021.

HYPERA S.A.

Adalmario Ghovatto Satheler do Couto

Investor Relations Officer